Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,148.95 9.69 0.31%
FTSE 100 6,611.02 26.85 0.41%
DAX 9,381.96 64.14 0.69%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Chelsea Therapeutics to Present at the 25th Annual ROTH Conference



Chelsea Therapeutics to Present at the 25th Annual ROTH Conference

CHARLOTTE, N.C., March 12, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 25^TH Annual
ROTH Conference at 3:30 PM PT on Tuesday, March 19, 2013 in Dana Point, CA.

Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a
corporate update and an overview of the Northera™ (droxidopa) development
program.

Mr. Oliveto's presentation will be webcast live and archived for 30 days on
Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a variety
of human diseases, including central nervous system disorders. Chelsea is
currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a
novel, late-stage, orally-active therapeutic agent for the treatment of
symptomatic neurogenic orthostatic hypotension in patients with primary
autonomic failure. For more information about the Company, visit
www.chelseatherapeutics.com

CONTACT: Investors:
         Fara Berkowitz/Susan Kim
         Argot Partners
         212-600-1902
         fara@argotpartners.com
         susan@argotpartners.com
        
         Media:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Chelsea Therapeutics Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement